Clorox Co-The

Clorox’s director deferred‑compensation plan, tied to dividend‑reinvestment DSUs, boosts board equity by 0.06%—offering insight into governance, risks and strategic improvements.

Clorox insider buys: VP and chief of staff each purchase ~35,000 shares, nudging insider ownership to 2.4 %—small move, no price impact, but a sign of management aligning with shareholders.

Clorox insiders file modest March 2026 trades, keeping their stakes and showing confidence in the brand while staying compliant with SEC rules.

Clorox’s steady $15B market cap, 15× P/E and eco‑friendly product focus keep it a defensively solid staple—investors see long‑term resilience amid modest price dips.

Clorox’s CFO will speak at the Citi Global Consumer & Retail Conference, linking financial performance to sustainability and consumer well‑being, and providing a livestream and replay for investors.

Clorox’s Q2 earnings dip: revenue flat, EPS down, investors pull back—learn how the household‑cleaning brand is navigating margin pressure and market shifts.

Clorox’s Q2 earnings miss shows margin squeeze, regulatory pressure, and price‑war risks, yet highlights eco‑friendly growth and data‑driven pricing as key recovery paths.

Clorox institutional trades show a balanced mix of buying and selling—hedge funds and asset managers stay active yet unchanged on value, keeping the stock steady within its 52‑week range.

Clorox’s $2.25 B buy of GOJO expands its hygiene dominance to 55% of the U.S. hand‑sanitizer market, delivering $150‑$170 M cash flow and smart‑dispenser synergies—but the debt‑backed deal adds 0.4x leverage risk that investors must watch closely.

Clorox’s Q2 2026 webcast, new allergen‑neutraliser launch and ERP upgrade show the company’s focus on health‑conscious products, operational efficiency and dividend‑growth, even as analysts tighten price targets. Discover how these moves shape its n…